Stem definition | Drug id | CAS RN |
---|---|---|
463 | 58-08-2 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
0.40 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 21.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 51.77 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 98 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.63 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.64 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 26, 1948 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 2541.84 | 9.41 | 3482 | 244269 | 142438 | 46295873 |
Toxicity to various agents | 1987.59 | 9.41 | 3816 | 243935 | 207950 | 46230361 |
Infusion related reaction | 628.75 | 9.41 | 1547 | 246204 | 99661 | 46338650 |
Overdose | 526.89 | 9.41 | 1455 | 246296 | 100524 | 46337787 |
Acute hepatic failure | 380.04 | 9.41 | 429 | 247322 | 14292 | 46424019 |
Metabolic acidosis | 373.08 | 9.41 | 708 | 247043 | 38072 | 46400239 |
Intentional product misuse | 370.49 | 9.41 | 791 | 246960 | 46337 | 46391974 |
Blood pressure fluctuation | 309.22 | 9.41 | 569 | 247182 | 29879 | 46408432 |
Hepatotoxicity | 275.20 | 9.41 | 484 | 247267 | 24525 | 46413786 |
Sinusitis | 259.86 | 9.41 | 1367 | 246384 | 128401 | 46309910 |
Exposure to toxic agent | 241.23 | 9.41 | 144 | 247607 | 1870 | 46436441 |
Anion gap | 236.35 | 9.41 | 115 | 247636 | 958 | 46437353 |
Product dose omission issue | 200.09 | 9.41 | 368 | 247383 | 168152 | 46270159 |
Intentional overdose | 162.09 | 9.41 | 729 | 247022 | 64215 | 46374096 |
Respiratory arrest | 152.62 | 9.41 | 460 | 247291 | 33356 | 46404955 |
Coagulopathy | 144.72 | 9.41 | 310 | 247441 | 18189 | 46420122 |
Depressed level of consciousness | 144.45 | 9.41 | 567 | 247184 | 47002 | 46391309 |
Cardio-respiratory arrest | 144.16 | 9.41 | 665 | 247086 | 59204 | 46379107 |
Psoriasis | 135.74 | 9.41 | 130 | 247621 | 78474 | 46359837 |
Injection site pain | 132.50 | 9.41 | 228 | 247523 | 106924 | 46331387 |
Diarrhoea | 119.56 | 9.41 | 2172 | 245579 | 557430 | 45880881 |
Poisoning | 115.85 | 9.41 | 240 | 247511 | 13754 | 46424557 |
Oxygen saturation decreased | 109.03 | 9.41 | 684 | 247067 | 68480 | 46369831 |
Hepatic failure | 107.74 | 9.41 | 406 | 247345 | 33010 | 46405301 |
Device expulsion | 101.74 | 9.41 | 13 | 247738 | 27529 | 46410782 |
Heart rate decreased | 101.10 | 9.41 | 384 | 247367 | 31339 | 46406972 |
Respiratory depression | 100.82 | 9.41 | 203 | 247548 | 11397 | 46426914 |
Acute lung injury | 100.53 | 9.41 | 70 | 247681 | 1201 | 46437110 |
Ergot poisoning | 97.49 | 9.41 | 39 | 247712 | 190 | 46438121 |
Blood pressure increased | 97.15 | 9.41 | 1064 | 246687 | 125602 | 46312709 |
Medication error | 96.72 | 9.41 | 372 | 247379 | 30539 | 46407772 |
Blood pressure diastolic abnormal | 92.62 | 9.41 | 139 | 247612 | 6155 | 46432156 |
Hepatic necrosis | 87.18 | 9.41 | 127 | 247624 | 5474 | 46432837 |
Intentional product use issue | 85.69 | 9.41 | 526 | 247225 | 52254 | 46386057 |
Pyroglutamate increased | 82.71 | 9.41 | 42 | 247709 | 387 | 46437924 |
Body temperature increased | 82.59 | 9.41 | 305 | 247446 | 24556 | 46413755 |
Drug ineffective | 82.40 | 9.41 | 2860 | 244891 | 674978 | 45763333 |
Coma | 82.17 | 9.41 | 561 | 247190 | 57788 | 46380523 |
Infusion site pain | 80.93 | 9.41 | 171 | 247580 | 9936 | 46428375 |
Analgesic drug level increased | 77.60 | 9.41 | 64 | 247687 | 1430 | 46436881 |
Suspected suicide | 75.93 | 9.41 | 108 | 247643 | 4553 | 46433758 |
Heart rate increased | 72.18 | 9.41 | 659 | 247092 | 74132 | 46364179 |
Blood pressure systolic abnormal | 71.63 | 9.41 | 115 | 247636 | 5402 | 46432909 |
Disease progression | 70.53 | 9.41 | 248 | 247503 | 91052 | 46347259 |
Infusion site swelling | 70.20 | 9.41 | 116 | 247635 | 5583 | 46432728 |
Injection site erythema | 68.99 | 9.41 | 186 | 247565 | 74241 | 46364070 |
Blood pressure diastolic decreased | 68.57 | 9.41 | 198 | 247553 | 14013 | 46424298 |
Nasopharyngitis | 68.41 | 9.41 | 1173 | 246578 | 152825 | 46285486 |
Exposure via ingestion | 68.13 | 9.41 | 88 | 247663 | 3379 | 46434932 |
Blood pressure systolic increased | 67.23 | 9.41 | 317 | 247434 | 28470 | 46409841 |
Injection site reaction | 66.56 | 9.41 | 94 | 247657 | 47755 | 46390556 |
Dyspnoea | 66.05 | 9.41 | 2160 | 245591 | 513388 | 45924923 |
Throat irritation | 65.13 | 9.41 | 315 | 247436 | 28586 | 46409725 |
Suicide attempt | 64.79 | 9.41 | 507 | 247244 | 54529 | 46383782 |
Cardiac failure congestive | 64.51 | 9.41 | 259 | 247492 | 91491 | 46346820 |
Drug abuse | 64.41 | 9.41 | 565 | 247186 | 62843 | 46375468 |
Liver injury | 64.19 | 9.41 | 209 | 247542 | 15792 | 46422519 |
Hypotension | 59.57 | 9.41 | 1636 | 246115 | 230953 | 46207358 |
Injection site pruritus | 59.44 | 9.41 | 74 | 247677 | 39669 | 46398642 |
Infusion site erythema | 58.55 | 9.41 | 127 | 247624 | 7515 | 46430796 |
Cardiac arrest | 58.45 | 9.41 | 735 | 247016 | 89664 | 46348647 |
Joint swelling | 57.63 | 9.41 | 1218 | 246533 | 164855 | 46273456 |
Hospitalisation | 57.55 | 9.41 | 160 | 247591 | 63225 | 46375086 |
Accidental overdose | 55.96 | 9.41 | 233 | 247518 | 19833 | 46418478 |
Hepatic enzyme increased | 55.91 | 9.41 | 672 | 247079 | 81115 | 46357196 |
Migraine | 54.45 | 9.41 | 590 | 247161 | 69436 | 46368875 |
Wrong technique in product usage process | 54.29 | 9.41 | 131 | 247620 | 54291 | 46384020 |
No adverse event | 54.12 | 9.41 | 61 | 247690 | 34170 | 46404141 |
Osteonecrosis of jaw | 53.64 | 9.41 | 62 | 247689 | 34340 | 46403971 |
Alopecia | 52.31 | 9.41 | 580 | 247171 | 161834 | 46276477 |
Muscle injury | 52.00 | 9.41 | 93 | 247658 | 4773 | 46433538 |
Drug resistance | 51.80 | 9.41 | 14 | 247737 | 17354 | 46420957 |
Sedation complication | 51.51 | 9.41 | 79 | 247672 | 3566 | 46434745 |
International normalised ratio increased | 51.43 | 9.41 | 425 | 247326 | 46458 | 46391853 |
Mucosal inflammation | 50.88 | 9.41 | 80 | 247671 | 38896 | 46399415 |
Myocardial infarction | 50.31 | 9.41 | 307 | 247444 | 97221 | 46341090 |
Anaemia | 50.25 | 9.41 | 1006 | 246745 | 254773 | 46183538 |
Psoriatic arthropathy | 50.07 | 9.41 | 72 | 247679 | 36307 | 46402004 |
Anion gap abnormal | 50.05 | 9.41 | 28 | 247723 | 319 | 46437992 |
Headache | 49.29 | 9.41 | 3052 | 244699 | 475300 | 45963011 |
Ear pain | 49.21 | 9.41 | 240 | 247511 | 21852 | 46416459 |
Substance abuse | 48.90 | 9.41 | 83 | 247668 | 4084 | 46434227 |
Alanine aminotransferase increased | 48.85 | 9.41 | 699 | 247052 | 87752 | 46350559 |
Soft tissue disorder | 48.63 | 9.41 | 83 | 247668 | 4103 | 46434208 |
Heart rate irregular | 48.09 | 9.41 | 211 | 247540 | 18380 | 46419931 |
Product quality issue | 47.65 | 9.41 | 72 | 247679 | 35576 | 46402735 |
Crystal urine present | 47.52 | 9.41 | 45 | 247706 | 1214 | 46437097 |
Folliculitis | 47.42 | 9.41 | 103 | 247648 | 6100 | 46432211 |
Electric shock | 47.41 | 9.41 | 39 | 247712 | 868 | 46437443 |
Death | 46.68 | 9.41 | 2202 | 245549 | 333346 | 46104965 |
Drug hypersensitivity | 46.10 | 9.41 | 965 | 246786 | 242860 | 46195451 |
Neutropenia | 45.87 | 9.41 | 512 | 247239 | 142692 | 46295619 |
Infusion site extravasation | 45.70 | 9.41 | 92 | 247659 | 5164 | 46433147 |
Infusion site pruritus | 44.33 | 9.41 | 68 | 247683 | 3070 | 46435241 |
Neonatal hypoxia | 43.98 | 9.41 | 29 | 247722 | 453 | 46437858 |
Therapy cessation | 43.70 | 9.41 | 46 | 247705 | 26583 | 46411728 |
Sopor | 42.89 | 9.41 | 26 | 247725 | 19802 | 46418509 |
Neuropathy peripheral | 42.37 | 9.41 | 295 | 247456 | 90598 | 46347713 |
White blood cells urine positive | 40.82 | 9.41 | 76 | 247675 | 4024 | 46434287 |
Duodenal ulcer perforation | 39.62 | 9.41 | 117 | 247634 | 8385 | 46429926 |
Cardiac failure | 39.50 | 9.41 | 255 | 247496 | 79693 | 46358618 |
Injection site bruising | 39.46 | 9.41 | 81 | 247670 | 35555 | 46402756 |
Administration site swelling | 39.02 | 9.41 | 39 | 247712 | 1126 | 46437185 |
Palmar-plantar erythrodysaesthesia syndrome | 38.70 | 9.41 | 31 | 247720 | 20420 | 46417891 |
Anti-cyclic citrullinated peptide antibody positive | 38.44 | 9.41 | 202 | 247549 | 18943 | 46419368 |
Aspartate aminotransferase increased | 38.05 | 9.41 | 608 | 247143 | 78092 | 46360219 |
Injection site swelling | 37.95 | 9.41 | 100 | 247651 | 40227 | 46398084 |
Ill-defined disorder | 37.20 | 9.41 | 257 | 247494 | 26570 | 46411741 |
Urinary sediment present | 37.03 | 9.41 | 47 | 247704 | 1773 | 46436538 |
Creatinine renal clearance decreased | 36.91 | 9.41 | 100 | 247651 | 6820 | 46431491 |
Muscle spasticity | 36.87 | 9.41 | 139 | 247612 | 11301 | 46427010 |
Decreased appetite | 36.66 | 9.41 | 767 | 246984 | 193069 | 46245242 |
Product use in unapproved indication | 36.41 | 9.41 | 305 | 247446 | 89968 | 46348343 |
Interstitial lung disease | 36.22 | 9.41 | 155 | 247596 | 53794 | 46384517 |
Off label use | 35.46 | 9.41 | 1651 | 246100 | 378190 | 46060121 |
Body temperature fluctuation | 35.26 | 9.41 | 46 | 247705 | 1784 | 46436527 |
Administration site pain | 35.16 | 9.41 | 29 | 247722 | 648 | 46437663 |
Product substitution issue | 34.98 | 9.41 | 18 | 247733 | 15013 | 46423298 |
Bone marrow failure | 34.96 | 9.41 | 65 | 247686 | 29604 | 46408707 |
Lower respiratory tract infection | 34.78 | 9.41 | 446 | 247305 | 54643 | 46383668 |
Body temperature decreased | 34.54 | 9.41 | 152 | 247599 | 13257 | 46425054 |
Respiratory rate increased | 34.46 | 9.41 | 136 | 247615 | 11297 | 46427014 |
Injection site warmth | 34.34 | 9.41 | 15 | 247736 | 13757 | 46424554 |
Helicobacter infection | 34.09 | 9.41 | 138 | 247613 | 11598 | 46426713 |
Acidosis | 33.74 | 9.41 | 133 | 247618 | 11041 | 46427270 |
Lymphocyte count decreased | 33.64 | 9.41 | 242 | 247509 | 25347 | 46412964 |
Hypothermia | 33.61 | 9.41 | 141 | 247610 | 12042 | 46426269 |
Malignant neoplasm progression | 33.15 | 9.41 | 205 | 247546 | 64721 | 46373590 |
Infusion site nodule | 32.78 | 9.41 | 33 | 247718 | 961 | 46437350 |
Blood pressure diastolic increased | 32.54 | 9.41 | 87 | 247664 | 5887 | 46432424 |
Jaundice cholestatic | 31.28 | 9.41 | 77 | 247674 | 4952 | 46433359 |
Maternal exposure during pregnancy | 31.13 | 9.41 | 371 | 247380 | 102178 | 46336133 |
Urine abnormality | 31.01 | 9.41 | 82 | 247669 | 5512 | 46432799 |
Cerebrovascular accident | 30.87 | 9.41 | 365 | 247386 | 100674 | 46337637 |
Red blood cells urine positive | 30.69 | 9.41 | 52 | 247699 | 2555 | 46435756 |
Infusion site bruising | 30.41 | 9.41 | 39 | 247712 | 1487 | 46436824 |
Product prescribing error | 30.32 | 9.41 | 37 | 247714 | 20010 | 46418301 |
Brain death | 30.22 | 9.41 | 54 | 247697 | 2769 | 46435542 |
Cognitive disorder | 30.17 | 9.41 | 314 | 247437 | 36569 | 46401742 |
Surgery | 28.93 | 9.41 | 69 | 247682 | 28716 | 46409595 |
Posterior reversible encephalopathy syndrome | 28.59 | 9.41 | 23 | 247728 | 15118 | 46423193 |
Liver transplant | 28.17 | 9.41 | 48 | 247703 | 2369 | 46435942 |
Therapy interrupted | 28.12 | 9.41 | 11 | 247740 | 10780 | 46427531 |
Brain oedema | 28.11 | 9.41 | 136 | 247615 | 12342 | 46425969 |
Prothrombin time prolonged | 28.00 | 9.41 | 113 | 247638 | 9483 | 46428828 |
Drug screen positive | 27.93 | 9.41 | 63 | 247688 | 3828 | 46434483 |
Haemolysis | 27.87 | 9.41 | 83 | 247668 | 5976 | 46432335 |
Paraesthesia | 27.72 | 9.41 | 447 | 247304 | 116990 | 46321321 |
Red cell distribution width increased | 27.70 | 9.41 | 97 | 247654 | 7607 | 46430704 |
Ear pruritus | 27.26 | 9.41 | 44 | 247707 | 2076 | 46436235 |
Blood calcium decreased | 27.21 | 9.41 | 159 | 247592 | 15514 | 46422797 |
Neutrophil percentage increased | 26.99 | 9.41 | 50 | 247701 | 2637 | 46435674 |
Lymphocyte percentage decreased | 26.83 | 9.41 | 50 | 247701 | 2649 | 46435662 |
Intervertebral discitis | 26.46 | 9.41 | 48 | 247703 | 2491 | 46435820 |
Anion gap increased | 26.46 | 9.41 | 36 | 247715 | 1455 | 46436856 |
Analgesic drug level above therapeutic | 26.29 | 9.41 | 15 | 247736 | 178 | 46438133 |
Product storage error | 26.16 | 9.41 | 15 | 247736 | 11777 | 46426534 |
Dyspnoea exertional | 26.08 | 9.41 | 158 | 247593 | 50131 | 46388180 |
Hypomania | 26.05 | 9.41 | 66 | 247685 | 4322 | 46433989 |
Somnolence | 25.88 | 9.41 | 1046 | 246705 | 155475 | 46282836 |
Hypertensive crisis | 25.31 | 9.41 | 21 | 247730 | 13594 | 46424717 |
Blood pH decreased | 25.29 | 9.41 | 48 | 247703 | 2579 | 46435732 |
Pericarditis | 25.22 | 9.41 | 215 | 247536 | 23712 | 46414599 |
Injection site rash | 25.19 | 9.41 | 28 | 247723 | 15785 | 46422526 |
Irritable bowel syndrome | 25.18 | 9.41 | 162 | 247589 | 16353 | 46421958 |
Foetal exposure during pregnancy | 24.76 | 9.41 | 82 | 247669 | 30665 | 46407646 |
Red blood cell sedimentation rate abnormal | 24.22 | 9.41 | 22 | 247729 | 13627 | 46424684 |
Ventricular arrhythmia | 24.12 | 9.41 | 55 | 247696 | 3366 | 46434945 |
Pain | 24.06 | 9.41 | 2886 | 244865 | 474062 | 45964249 |
Bradypnoea | 23.85 | 9.41 | 51 | 247700 | 2988 | 46435323 |
Medication overuse headache | 23.69 | 9.41 | 20 | 247731 | 462 | 46437849 |
Poor venous access | 23.58 | 9.41 | 97 | 247654 | 8211 | 46430100 |
Unevaluable event | 23.46 | 9.41 | 146 | 247605 | 46029 | 46392282 |
Cholecystitis chronic | 23.34 | 9.41 | 114 | 247637 | 10385 | 46427926 |
Sleep disorder due to general medical condition, insomnia type | 23.29 | 9.41 | 71 | 247680 | 5178 | 46433133 |
Unresponsive to stimuli | 23.14 | 9.41 | 267 | 247484 | 31907 | 46406404 |
Neoplasm progression | 23.01 | 9.41 | 69 | 247682 | 26614 | 46411697 |
Encephalopathy | 22.94 | 9.41 | 276 | 247475 | 33313 | 46404998 |
Ductus arteriosus premature closure | 22.94 | 9.41 | 17 | 247734 | 323 | 46437988 |
Precancerous cells present | 22.73 | 9.41 | 30 | 247721 | 1177 | 46437134 |
Myelodysplastic syndrome | 22.72 | 9.41 | 30 | 247721 | 15681 | 46422630 |
Pancytopenia | 22.39 | 9.41 | 317 | 247434 | 84741 | 46353570 |
Administration site erythema | 22.22 | 9.41 | 21 | 247730 | 565 | 46437746 |
Electrocardiogram QRS complex abnormal | 21.32 | 9.41 | 14 | 247737 | 217 | 46438094 |
Oedema peripheral | 21.31 | 9.41 | 665 | 247086 | 159041 | 46279270 |
Asthma | 21.08 | 9.41 | 350 | 247401 | 91192 | 46347119 |
Hand deformity | 21.01 | 9.41 | 278 | 247473 | 34296 | 46404015 |
Bone erosion | 20.96 | 9.41 | 12 | 247739 | 9431 | 46428880 |
Bacterial test | 20.54 | 9.41 | 29 | 247722 | 1214 | 46437097 |
Injection site mass | 20.46 | 9.41 | 30 | 247721 | 15010 | 46423301 |
Urine leukocyte esterase positive | 20.42 | 9.41 | 43 | 247708 | 2492 | 46435819 |
Epistaxis | 20.14 | 9.41 | 231 | 247520 | 64074 | 46374237 |
Hyponatraemia | 20.01 | 9.41 | 398 | 247353 | 100934 | 46337377 |
Pyroglutamic acidosis | 19.97 | 9.41 | 14 | 247737 | 243 | 46438068 |
Plasma cell myeloma | 19.92 | 9.41 | 146 | 247605 | 44332 | 46393979 |
Hyperkalaemia | 19.69 | 9.41 | 173 | 247578 | 50536 | 46387775 |
Dysgeusia | 19.56 | 9.41 | 130 | 247621 | 40361 | 46397950 |
Drug interaction | 19.45 | 9.41 | 880 | 246871 | 202214 | 46236097 |
Muscle spasms | 19.37 | 9.41 | 501 | 247250 | 122612 | 46315699 |
Diabetes mellitus | 19.35 | 9.41 | 171 | 247580 | 49894 | 46388417 |
Injection site urticaria | 19.27 | 9.41 | 21 | 247730 | 11946 | 46426365 |
Pneumocystis jirovecii pneumonia | 19.24 | 9.41 | 32 | 247719 | 15216 | 46423095 |
Night sweats | 19.09 | 9.41 | 225 | 247526 | 27025 | 46411286 |
Renal impairment | 18.93 | 9.41 | 279 | 247472 | 74093 | 46364218 |
Specific gravity urine decreased | 18.92 | 9.41 | 17 | 247734 | 428 | 46437883 |
Osmolar gap | 18.91 | 9.41 | 10 | 247741 | 101 | 46438210 |
Therapeutic product effect decreased | 18.61 | 9.41 | 572 | 247179 | 82029 | 46356282 |
Fracture | 18.61 | 9.41 | 37 | 247714 | 16434 | 46421877 |
Blood creatine increased | 18.45 | 9.41 | 60 | 247691 | 4530 | 46433781 |
Blood urine present | 18.43 | 9.41 | 120 | 247631 | 12162 | 46426149 |
Weight increased | 18.07 | 9.41 | 1056 | 246695 | 163417 | 46274894 |
Coronary artery disease | 18.05 | 9.41 | 105 | 247646 | 33647 | 46404664 |
Neurotoxicity | 18.05 | 9.41 | 28 | 247723 | 13689 | 46424622 |
Dizziness | 17.76 | 9.41 | 1560 | 246191 | 338854 | 46099457 |
Coma hepatic | 17.71 | 9.41 | 19 | 247732 | 597 | 46437714 |
Drug abuser | 17.52 | 9.41 | 47 | 247704 | 3186 | 46435125 |
Toxicologic test abnormal | 17.41 | 9.41 | 20 | 247731 | 679 | 46437632 |
PCO2 decreased | 17.24 | 9.41 | 27 | 247724 | 1241 | 46437070 |
Smear cervix abnormal | 17.24 | 9.41 | 40 | 247711 | 2476 | 46435835 |
Ejection fraction decreased | 17.24 | 9.41 | 44 | 247707 | 17893 | 46420418 |
Pneumonia viral | 16.99 | 9.41 | 75 | 247676 | 6549 | 46431762 |
Device dislocation | 16.97 | 9.41 | 59 | 247692 | 21743 | 46416568 |
Blood bilirubin increased | 16.85 | 9.41 | 265 | 247486 | 33919 | 46404392 |
Drug-induced liver injury | 16.69 | 9.41 | 207 | 247544 | 25161 | 46413150 |
Cystitis | 16.69 | 9.41 | 316 | 247435 | 41925 | 46396386 |
Band neutrophil count increased | 16.42 | 9.41 | 14 | 247737 | 328 | 46437983 |
Infusion site urticaria | 16.38 | 9.41 | 20 | 247731 | 725 | 46437586 |
Anaphylactic shock | 16.37 | 9.41 | 54 | 247697 | 20220 | 46418091 |
Tachycardia | 16.27 | 9.41 | 665 | 247086 | 98957 | 46339354 |
Pneumonia | 16.21 | 9.41 | 1749 | 246002 | 374571 | 46063740 |
Pathogen resistance | 16.09 | 9.41 | 6 | 247745 | 6054 | 46432257 |
Polyneuropathy | 16.06 | 9.41 | 23 | 247728 | 11621 | 46426690 |
Osteonecrosis | 16.05 | 9.41 | 76 | 247675 | 25668 | 46412643 |
Traumatic liver injury | 16.05 | 9.41 | 13 | 247738 | 283 | 46438028 |
Intentional self-injury | 15.87 | 9.41 | 70 | 247681 | 24096 | 46414215 |
Therapeutic response shortened | 15.79 | 9.41 | 62 | 247689 | 5137 | 46433174 |
Disease recurrence | 15.76 | 9.41 | 48 | 247703 | 18423 | 46419888 |
Antidepressant drug level above therapeutic | 15.63 | 9.41 | 14 | 247737 | 351 | 46437960 |
Renal papillary necrosis | 15.54 | 9.41 | 12 | 247739 | 243 | 46438068 |
Feeling abnormal | 15.42 | 9.41 | 526 | 247225 | 124534 | 46313777 |
Adverse event | 15.41 | 9.41 | 112 | 247639 | 34072 | 46404239 |
Infusion site haemorrhage | 15.38 | 9.41 | 35 | 247716 | 2139 | 46436172 |
Transplant rejection | 15.28 | 9.41 | 17 | 247734 | 9579 | 46428732 |
Administration site pruritus | 15.27 | 9.41 | 13 | 247738 | 304 | 46438007 |
Hypokalaemia | 15.27 | 9.41 | 353 | 247398 | 87671 | 46350640 |
Second primary malignancy | 15.15 | 9.41 | 8 | 247743 | 6576 | 46431735 |
Synovitis | 15.13 | 9.41 | 428 | 247323 | 60647 | 46377664 |
Drug use disorder | 15.07 | 9.41 | 40 | 247711 | 2695 | 46435616 |
Device issue | 14.93 | 9.41 | 55 | 247696 | 19925 | 46418386 |
Femur fracture | 14.91 | 9.41 | 125 | 247626 | 36872 | 46401439 |
Memory impairment | 14.89 | 9.41 | 305 | 247446 | 77032 | 46361279 |
Cytomegalovirus infection | 14.88 | 9.41 | 48 | 247703 | 18096 | 46420215 |
Mean cell haemoglobin concentration increased | 14.87 | 9.41 | 15 | 247736 | 438 | 46437873 |
Lactic acidosis | 14.85 | 9.41 | 112 | 247639 | 33797 | 46404514 |
Haemoglobin urine present | 14.84 | 9.41 | 18 | 247733 | 648 | 46437663 |
Abortion spontaneous | 14.78 | 9.41 | 154 | 247597 | 43492 | 46394819 |
Inflammation | 14.75 | 9.41 | 351 | 247400 | 48430 | 46389881 |
Post-traumatic stress disorder | 14.58 | 9.41 | 51 | 247700 | 3997 | 46434314 |
Vitamin K deficiency | 14.57 | 9.41 | 15 | 247736 | 449 | 46437862 |
Ageusia | 14.54 | 9.41 | 24 | 247727 | 11448 | 46426863 |
Self-medication | 14.52 | 9.41 | 34 | 247717 | 2118 | 46436193 |
Underdose | 14.51 | 9.41 | 54 | 247697 | 19504 | 46418807 |
Angioedema | 14.50 | 9.41 | 136 | 247615 | 39206 | 46399105 |
Haematocrit decreased | 14.45 | 9.41 | 264 | 247487 | 34793 | 46403518 |
Transaminases increased | 14.37 | 9.41 | 217 | 247534 | 27544 | 46410767 |
Respiratory disorder | 14.37 | 9.41 | 214 | 247537 | 27086 | 46411225 |
Therapeutic product effect incomplete | 14.24 | 9.41 | 311 | 247440 | 77842 | 46360469 |
Injection site haemorrhage | 14.20 | 9.41 | 59 | 247692 | 20650 | 46417661 |
Dry skin | 14.18 | 9.41 | 144 | 247607 | 40872 | 46397439 |
Chills | 14.11 | 9.41 | 634 | 247117 | 95398 | 46342913 |
Blood parathyroid hormone decreased | 14.11 | 9.41 | 3 | 247748 | 4378 | 46433933 |
Breast cancer | 14.06 | 9.41 | 164 | 247587 | 45354 | 46392957 |
Activated partial thromboplastin time prolonged | 14.04 | 9.41 | 73 | 247678 | 6816 | 46431495 |
Administration site extravasation | 13.99 | 9.41 | 17 | 247734 | 613 | 46437698 |
Ear infection | 13.97 | 9.41 | 185 | 247566 | 22828 | 46415483 |
Transfusion-related acute lung injury | 13.94 | 9.41 | 8 | 247743 | 96 | 46438215 |
Wound | 13.88 | 9.41 | 311 | 247440 | 42491 | 46395820 |
Gastrointestinal toxicity | 13.88 | 9.41 | 3 | 247748 | 4328 | 46433983 |
Myelocyte count increased | 13.87 | 9.41 | 13 | 247738 | 346 | 46437965 |
White blood cell count decreased | 13.84 | 9.41 | 472 | 247279 | 111759 | 46326552 |
Derailment | 13.83 | 9.41 | 7 | 247744 | 64 | 46438247 |
Oral discomfort | 13.77 | 9.41 | 13 | 247738 | 7905 | 46430406 |
Haematotoxicity | 13.77 | 9.41 | 10 | 247741 | 6923 | 46431388 |
Diabetic ketoacidosis | 13.69 | 9.41 | 50 | 247701 | 18160 | 46420151 |
Orthostatic hypotension | 13.65 | 9.41 | 195 | 247556 | 24463 | 46413848 |
Musculoskeletal disorder | 13.54 | 9.41 | 40 | 247711 | 15505 | 46422806 |
Transplant dysfunction | 13.54 | 9.41 | 4 | 247747 | 4678 | 46433633 |
Device use error | 13.54 | 9.41 | 5 | 247746 | 5076 | 46433235 |
Accidental death | 13.49 | 9.41 | 30 | 247721 | 1805 | 46436506 |
Cholelithiasis | 13.48 | 9.41 | 284 | 247467 | 38397 | 46399914 |
Asphyxia | 13.43 | 9.41 | 60 | 247691 | 5266 | 46433045 |
Blood creatinine decreased | 13.41 | 9.41 | 55 | 247696 | 4649 | 46433662 |
Infective pulmonary exacerbation of cystic fibrosis | 13.34 | 9.41 | 23 | 247728 | 10784 | 46427527 |
Culture urine positive | 13.34 | 9.41 | 44 | 247707 | 3347 | 46434964 |
Arthralgia | 13.28 | 9.41 | 2165 | 245586 | 362438 | 46075873 |
Duodenal stenosis | 13.19 | 9.41 | 16 | 247735 | 576 | 46437735 |
Flushing | 13.13 | 9.41 | 442 | 247309 | 64172 | 46374139 |
Magnesium deficiency | 13.10 | 9.41 | 14 | 247737 | 438 | 46437873 |
Cells in urine | 13.05 | 9.41 | 9 | 247742 | 152 | 46438159 |
Procedural anxiety | 13.02 | 9.41 | 15 | 247736 | 511 | 46437800 |
Blood count abnormal | 12.85 | 9.41 | 50 | 247701 | 17828 | 46420483 |
Nail bed inflammation | 12.79 | 9.41 | 13 | 247738 | 383 | 46437928 |
Parkinsonism | 12.74 | 9.41 | 14 | 247737 | 7934 | 46430377 |
Sinus tachycardia | 12.71 | 9.41 | 173 | 247578 | 21476 | 46416835 |
Anticholinergic syndrome | 12.69 | 9.41 | 29 | 247722 | 1777 | 46436534 |
Pulmonary arterial hypertension | 12.65 | 9.41 | 83 | 247668 | 25845 | 46412466 |
Joint stiffness | 12.61 | 9.41 | 88 | 247663 | 27020 | 46411291 |
Epilepsy | 12.61 | 9.41 | 74 | 247677 | 23664 | 46414647 |
Renal failure | 12.59 | 9.41 | 484 | 247267 | 113110 | 46325201 |
Congestive hepatopathy | 12.59 | 9.41 | 35 | 247716 | 2423 | 46435888 |
Autonomic dysreflexia | 12.57 | 9.41 | 10 | 247741 | 212 | 46438099 |
Device related thrombosis | 12.54 | 9.41 | 23 | 247728 | 1204 | 46437107 |
Drug dependence | 12.50 | 9.41 | 161 | 247590 | 19740 | 46418571 |
Full blood count decreased | 12.47 | 9.41 | 68 | 247683 | 22143 | 46416168 |
Diaphragmatic rupture | 12.41 | 9.41 | 10 | 247741 | 216 | 46438095 |
Labelled drug-drug interaction medication error | 12.40 | 9.41 | 18 | 247733 | 9043 | 46429268 |
Gestational diabetes | 12.38 | 9.41 | 12 | 247739 | 7207 | 46431104 |
Genital haemorrhage | 12.36 | 9.41 | 10 | 247741 | 6556 | 46431755 |
Sepsis | 12.28 | 9.41 | 593 | 247158 | 135421 | 46302890 |
Febrile bone marrow aplasia | 12.25 | 9.41 | 11 | 247740 | 6851 | 46431460 |
Oesophageal mucosal dissection | 12.24 | 9.41 | 5 | 247746 | 26 | 46438285 |
Administration site reaction | 12.22 | 9.41 | 10 | 247741 | 221 | 46438090 |
Gastrooesophageal reflux disease | 12.10 | 9.41 | 301 | 247450 | 74043 | 46364268 |
Urinary casts | 12.05 | 9.41 | 14 | 247737 | 481 | 46437830 |
Monocyte count increased | 11.99 | 9.41 | 56 | 247695 | 5008 | 46433303 |
Renal failure neonatal | 11.97 | 9.41 | 8 | 247743 | 128 | 46438183 |
Device malfunction | 11.95 | 9.41 | 34 | 247717 | 13340 | 46424971 |
Urine analysis abnormal | 11.95 | 9.41 | 49 | 247702 | 4141 | 46434170 |
Immunodeficiency | 11.89 | 9.41 | 114 | 247637 | 12992 | 46425319 |
Gallbladder injury | 11.88 | 9.41 | 24 | 247727 | 1350 | 46436961 |
Mean cell haemoglobin concentration decreased | 11.88 | 9.41 | 35 | 247716 | 2505 | 46435806 |
Treatment failure | 11.83 | 9.41 | 390 | 247361 | 92697 | 46345614 |
Sedation | 11.83 | 9.41 | 179 | 247572 | 22731 | 46415580 |
Adverse drug reaction | 11.78 | 9.41 | 165 | 247586 | 44197 | 46394114 |
Infusion site discomfort | 11.72 | 9.41 | 16 | 247735 | 649 | 46437662 |
Immune reconstitution inflammatory syndrome | 11.71 | 9.41 | 8 | 247743 | 5717 | 46432594 |
Cardiovascular disorder | 11.63 | 9.41 | 30 | 247721 | 12157 | 46426154 |
Hepatic encephalopathy | 11.63 | 9.41 | 93 | 247658 | 10064 | 46428247 |
Atypical femur fracture | 11.60 | 9.41 | 6 | 247745 | 4991 | 46433320 |
Postmortem blood drug level increased | 11.54 | 9.41 | 13 | 247738 | 432 | 46437879 |
Syncope | 11.52 | 9.41 | 447 | 247304 | 104356 | 46333955 |
Upper respiratory tract infection | 11.49 | 9.41 | 429 | 247322 | 63127 | 46375184 |
Galactorrhoea | 11.44 | 9.41 | 3 | 247748 | 3794 | 46434517 |
Hyperlipidaemia | 11.40 | 9.41 | 55 | 247696 | 18484 | 46419827 |
Hypomagnesaemia | 11.40 | 9.41 | 70 | 247681 | 22140 | 46416171 |
Gastric infection | 11.40 | 9.41 | 37 | 247714 | 2791 | 46435520 |
Angina unstable | 11.34 | 9.41 | 14 | 247737 | 7534 | 46430777 |
Ataxia | 11.32 | 9.41 | 37 | 247714 | 13893 | 46424418 |
Hepatic cirrhosis | 11.31 | 9.41 | 44 | 247707 | 15688 | 46422623 |
Renal disorder | 11.28 | 9.41 | 89 | 247662 | 26597 | 46411714 |
Diffuse large B-cell lymphoma | 11.23 | 9.41 | 9 | 247742 | 5929 | 46432382 |
Urine oxalate increased | 11.22 | 9.41 | 9 | 247742 | 193 | 46438118 |
Rash pruritic | 11.20 | 9.41 | 166 | 247585 | 44049 | 46394262 |
Visual acuity reduced | 11.19 | 9.41 | 70 | 247681 | 22043 | 46416268 |
Injection site induration | 11.10 | 9.41 | 16 | 247735 | 8063 | 46430248 |
Systemic inflammatory response syndrome | 11.01 | 9.41 | 57 | 247694 | 5314 | 46432997 |
Cystic fibrosis | 10.95 | 9.41 | 3 | 247748 | 3685 | 46434626 |
Malaise | 10.94 | 9.41 | 1566 | 246185 | 329666 | 46108645 |
Band neutrophil percentage increased | 10.92 | 9.41 | 9 | 247742 | 201 | 46438110 |
Anoxia | 10.89 | 9.41 | 10 | 247741 | 259 | 46438052 |
Treatment noncompliance | 10.86 | 9.41 | 103 | 247648 | 29628 | 46408683 |
Vein collapse | 10.81 | 9.41 | 14 | 247737 | 539 | 46437772 |
Osmolar gap abnormal | 10.78 | 9.41 | 5 | 247746 | 37 | 46438274 |
Blood methaemoglobin present | 10.75 | 9.41 | 6 | 247745 | 68 | 46438243 |
Opiates positive | 10.71 | 9.41 | 10 | 247741 | 265 | 46438046 |
Administration site bruise | 10.71 | 9.41 | 10 | 247741 | 265 | 46438046 |
Acute graft versus host disease | 10.68 | 9.41 | 4 | 247747 | 4026 | 46434285 |
Obstructive airways disorder | 10.64 | 9.41 | 36 | 247715 | 13376 | 46424935 |
Lupus vulgaris | 10.62 | 9.41 | 4 | 247747 | 16 | 46438295 |
Rheumatoid factor positive | 10.62 | 9.41 | 160 | 247591 | 20301 | 46418010 |
General physical health deterioration | 10.59 | 9.41 | 504 | 247247 | 115265 | 46323046 |
Extrapyramidal disorder | 10.55 | 9.41 | 28 | 247723 | 11240 | 46427071 |
Spinal cord abscess | 10.53 | 9.41 | 8 | 247743 | 158 | 46438153 |
Metastases to liver | 10.43 | 9.41 | 61 | 247690 | 19524 | 46418787 |
Gait inability | 10.43 | 9.41 | 128 | 247623 | 35075 | 46403236 |
Pericardial effusion | 10.43 | 9.41 | 86 | 247665 | 25457 | 46412854 |
Infusion site mass | 10.40 | 9.41 | 18 | 247733 | 900 | 46437411 |
Peripheral swelling | 10.38 | 9.41 | 974 | 246777 | 157097 | 46281214 |
Haemorrhage | 10.38 | 9.41 | 217 | 247534 | 54652 | 46383659 |
Septic shock | 10.36 | 9.41 | 231 | 247520 | 57662 | 46380649 |
Nightmare | 10.35 | 9.41 | 49 | 247702 | 16549 | 46421762 |
Head banging | 10.34 | 9.41 | 12 | 247739 | 412 | 46437899 |
Transient ischaemic attack | 10.30 | 9.41 | 127 | 247624 | 34776 | 46403535 |
Myelocyte percentage increased | 10.28 | 9.41 | 8 | 247743 | 164 | 46438147 |
Acute myocardial infarction | 10.26 | 9.41 | 114 | 247637 | 31810 | 46406501 |
Bursitis | 10.23 | 9.41 | 155 | 247596 | 19687 | 46418624 |
Glycosylated haemoglobin increased | 10.21 | 9.41 | 27 | 247724 | 10849 | 46427462 |
Temperature regulation disorder | 10.15 | 9.41 | 40 | 247711 | 3320 | 46434991 |
Infusion site irritation | 10.13 | 9.41 | 13 | 247738 | 496 | 46437815 |
Hypocalcaemia | 10.12 | 9.41 | 92 | 247659 | 26693 | 46411618 |
Mood swings | 10.12 | 9.41 | 48 | 247703 | 16204 | 46422107 |
Nose deformity | 10.11 | 9.41 | 7 | 247744 | 119 | 46438192 |
Metastases to bone | 10.09 | 9.41 | 53 | 247698 | 17423 | 46420888 |
Haemophagocytic lymphohistiocytosis | 10.07 | 9.41 | 18 | 247733 | 8324 | 46429987 |
Amenorrhoea | 10.03 | 9.41 | 20 | 247731 | 8875 | 46429436 |
Lower limb fracture | 10.03 | 9.41 | 33 | 247718 | 12365 | 46425946 |
Oedema | 10.00 | 9.41 | 275 | 247476 | 66796 | 46371515 |
Pharyngitis streptococcal | 9.95 | 9.41 | 78 | 247673 | 8390 | 46429921 |
C-reactive protein abnormal | 9.92 | 9.41 | 69 | 247682 | 21201 | 46417110 |
Bone pain | 9.92 | 9.41 | 182 | 247569 | 46708 | 46391603 |
Device difficult to use | 9.91 | 9.41 | 17 | 247734 | 7987 | 46430324 |
Akathisia | 9.91 | 9.41 | 16 | 247735 | 7698 | 46430613 |
Hypersensitivity vasculitis | 9.90 | 9.41 | 5 | 247746 | 4216 | 46434095 |
Hallucination, auditory | 9.87 | 9.41 | 27 | 247724 | 10729 | 46427582 |
Pulmonary mass | 9.84 | 9.41 | 55 | 247696 | 17802 | 46420509 |
Invasive ductal breast carcinoma | 9.74 | 9.41 | 11 | 247740 | 6157 | 46432154 |
Atrial fibrillation | 9.67 | 9.41 | 450 | 247301 | 103140 | 46335171 |
Eye infection | 9.63 | 9.41 | 82 | 247669 | 9041 | 46429270 |
Pregnancy with contraceptive device | 9.61 | 9.41 | 6 | 247745 | 4497 | 46433814 |
Administration site nodule | 9.58 | 9.41 | 5 | 247746 | 49 | 46438262 |
Electrolyte imbalance | 9.53 | 9.41 | 53 | 247698 | 17173 | 46421138 |
Abdominal discomfort | 9.52 | 9.41 | 682 | 247069 | 150483 | 46287828 |
Carnitine deficiency | 9.44 | 9.41 | 7 | 247744 | 133 | 46438178 |
Blood chloride increased | 9.44 | 9.41 | 33 | 247718 | 2586 | 46435725 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 1118.14 | 9.98 | 1666 | 118706 | 97826 | 29734280 |
Toxicity to various agents | 973.57 | 9.98 | 2174 | 118198 | 175009 | 29657097 |
Infusion related reaction | 374.81 | 9.98 | 622 | 119750 | 39942 | 29792164 |
Overdose | 345.07 | 9.98 | 926 | 119446 | 83411 | 29748695 |
Blood pressure fluctuation | 261.63 | 9.98 | 337 | 120035 | 17166 | 29814940 |
Intentional product misuse | 225.62 | 9.98 | 457 | 119915 | 34210 | 29797896 |
Acute hepatic failure | 206.11 | 9.98 | 246 | 120126 | 11581 | 29820525 |
Intentional overdose | 180.11 | 9.98 | 466 | 119906 | 41015 | 29791091 |
Drug ineffective | 149.52 | 9.98 | 783 | 119589 | 339604 | 29492502 |
Exposure to toxic agent | 131.83 | 9.98 | 72 | 120300 | 1053 | 29831053 |
Product dose omission issue | 103.12 | 9.98 | 130 | 120242 | 91501 | 29740605 |
Neonatal hypoxia | 98.17 | 9.98 | 37 | 120335 | 208 | 29831898 |
Hepatotoxicity | 98.17 | 9.98 | 222 | 120150 | 17923 | 29814183 |
Coagulopathy | 96.49 | 9.98 | 223 | 120149 | 18264 | 29813842 |
Anion gap | 94.63 | 9.98 | 48 | 120324 | 598 | 29831508 |
Cardio-respiratory arrest | 89.46 | 9.98 | 461 | 119911 | 56845 | 29775261 |
Heart rate decreased | 84.12 | 9.98 | 229 | 120143 | 20765 | 29811341 |
Respiratory arrest | 83.26 | 9.98 | 283 | 120089 | 28975 | 29803131 |
Oxygen saturation decreased | 81.16 | 9.98 | 368 | 120004 | 43072 | 29789034 |
Metabolic acidosis | 80.46 | 9.98 | 331 | 120041 | 37130 | 29794976 |
Blood pressure increased | 75.21 | 9.98 | 521 | 119851 | 71407 | 29760699 |
Myocardial infarction | 73.91 | 9.98 | 258 | 120114 | 125367 | 29706739 |
Diarrhoea | 73.36 | 9.98 | 926 | 119446 | 333177 | 29498929 |
Accidental overdose | 70.89 | 9.98 | 197 | 120175 | 18078 | 29814028 |
Hepatic necrosis | 66.71 | 9.98 | 80 | 120292 | 3783 | 29828323 |
Substance abuse | 63.65 | 9.98 | 107 | 120265 | 6933 | 29825173 |
Psoriasis | 61.95 | 9.98 | 48 | 120324 | 42458 | 29789648 |
Cardiac failure congestive | 60.63 | 9.98 | 158 | 120214 | 84249 | 29747857 |
Alanine aminotransferase increased | 56.07 | 9.98 | 499 | 119873 | 73777 | 29758329 |
Hypotension | 54.88 | 9.98 | 1120 | 119252 | 199445 | 29632661 |
Sinusitis | 51.83 | 9.98 | 268 | 120104 | 33077 | 29799029 |
Drug resistance | 50.02 | 9.98 | 10 | 120362 | 20123 | 29811983 |
Respiratory depression | 48.62 | 9.98 | 128 | 120244 | 11375 | 29820731 |
Cardiac failure | 46.59 | 9.98 | 175 | 120197 | 83243 | 29748863 |
Aspartate aminotransferase increased | 45.27 | 9.98 | 421 | 119951 | 63001 | 29769105 |
Heart rate irregular | 44.47 | 9.98 | 129 | 120243 | 12130 | 29819976 |
Product use in unapproved indication | 42.86 | 9.98 | 152 | 120220 | 73541 | 29758565 |
Blood pressure diastolic increased | 42.60 | 9.98 | 54 | 120318 | 2704 | 29829402 |
Treatment failure | 42.41 | 9.98 | 46 | 120326 | 34633 | 29797473 |
Poisoning | 41.50 | 9.98 | 120 | 120252 | 11262 | 29820844 |
Chills | 41.01 | 9.98 | 458 | 119914 | 71880 | 29760226 |
Liver injury | 40.74 | 9.98 | 126 | 120246 | 12274 | 29819832 |
Suicide attempt | 40.22 | 9.98 | 269 | 120103 | 36428 | 29795678 |
Blood pressure diastolic abnormal | 39.02 | 9.98 | 36 | 120336 | 1251 | 29830855 |
Medication error | 37.18 | 9.98 | 175 | 120197 | 20797 | 29811309 |
Exposure via ingestion | 37.01 | 9.98 | 49 | 120323 | 2562 | 29829544 |
Blood pressure systolic increased | 36.86 | 9.98 | 139 | 120233 | 14971 | 29817135 |
Drug abuse | 36.31 | 9.98 | 496 | 119876 | 81576 | 29750530 |
Cardiac arrest | 35.49 | 9.98 | 547 | 119825 | 92303 | 29739803 |
Depressed level of consciousness | 34.83 | 9.98 | 268 | 120104 | 37954 | 29794152 |
Analgesic drug level increased | 33.96 | 9.98 | 24 | 120348 | 565 | 29831541 |
Heart rate increased | 33.36 | 9.98 | 268 | 120104 | 38453 | 29793653 |
Blood pressure systolic abnormal | 32.46 | 9.98 | 35 | 120337 | 1472 | 29830634 |
Coronary artery disease | 32.02 | 9.98 | 98 | 120274 | 49614 | 29782492 |
Coma | 31.14 | 9.98 | 273 | 120099 | 40176 | 29791930 |
Hepatic failure | 30.63 | 9.98 | 238 | 120134 | 33805 | 29798301 |
Tachycardia | 29.95 | 9.98 | 439 | 119933 | 73300 | 29758806 |
Contraindicated product administered | 29.82 | 9.98 | 16 | 120356 | 17215 | 29814891 |
Interstitial lung disease | 28.81 | 9.98 | 134 | 120238 | 60063 | 29772043 |
Suspected suicide | 28.52 | 9.98 | 48 | 120324 | 3113 | 29828993 |
Infusion site extravasation | 27.96 | 9.98 | 42 | 120330 | 2471 | 29829635 |
Blood pH decreased | 27.91 | 9.98 | 40 | 120332 | 2255 | 29829851 |
Blood pressure diastolic decreased | 27.01 | 9.98 | 70 | 120302 | 6161 | 29825945 |
Neutrophil percentage increased | 26.45 | 9.98 | 35 | 120337 | 1829 | 29830277 |
Acute lung injury | 26.14 | 9.98 | 27 | 120345 | 1080 | 29831026 |
Anaemia | 25.96 | 9.98 | 637 | 119735 | 207355 | 29624751 |
Pyrexia | 25.87 | 9.98 | 1438 | 118934 | 293051 | 29539055 |
Toxic epidermal necrolysis | 25.69 | 9.98 | 141 | 120231 | 17799 | 29814307 |
International normalised ratio increased | 25.57 | 9.98 | 299 | 120073 | 47440 | 29784666 |
Neuropathy peripheral | 25.49 | 9.98 | 172 | 120200 | 70303 | 29761803 |
Methaemoglobinaemia | 25.20 | 9.98 | 40 | 120332 | 2470 | 29829636 |
Body temperature fluctuation | 24.79 | 9.98 | 28 | 120344 | 1241 | 29830865 |
Prothrombin time prolonged | 24.73 | 9.98 | 88 | 120284 | 9215 | 29822891 |
Urine sodium decreased | 24.49 | 9.98 | 13 | 120359 | 179 | 29831927 |
Stevens-Johnson syndrome | 23.83 | 9.98 | 136 | 120236 | 17420 | 29814686 |
Body temperature decreased | 23.70 | 9.98 | 89 | 120283 | 9566 | 29822540 |
Ergot poisoning | 23.67 | 9.98 | 10 | 120362 | 79 | 29832027 |
Fatigue | 23.44 | 9.98 | 1052 | 119320 | 319621 | 29512485 |
Unresponsive to stimuli | 23.37 | 9.98 | 184 | 120188 | 26235 | 29805871 |
Product prescribing error | 23.00 | 9.98 | 20 | 120352 | 16713 | 29815393 |
Oxygen saturation abnormal | 22.66 | 9.98 | 25 | 120347 | 1079 | 29831027 |
Infusion site pruritus | 22.58 | 9.98 | 19 | 120353 | 583 | 29831523 |
Brain death | 22.54 | 9.98 | 38 | 120334 | 2468 | 29829638 |
Infusion site pain | 22.28 | 9.98 | 39 | 120333 | 2611 | 29829495 |
Acidosis | 22.08 | 9.98 | 91 | 120281 | 10210 | 29821896 |
Lymphocyte percentage decreased | 21.99 | 9.98 | 34 | 120338 | 2052 | 29830054 |
Cerebrovascular accident | 21.87 | 9.98 | 222 | 120150 | 83255 | 29748851 |
Intentional product use issue | 21.68 | 9.98 | 233 | 120139 | 36207 | 29795899 |
Nasopharyngitis | 21.44 | 9.98 | 344 | 120028 | 58505 | 29773601 |
Depression | 21.10 | 9.98 | 247 | 120125 | 90190 | 29741916 |
Hospitalisation | 20.99 | 9.98 | 99 | 120273 | 44220 | 29787886 |
Infusion site swelling | 20.89 | 9.98 | 29 | 120343 | 1587 | 29830519 |
No adverse event | 20.32 | 9.98 | 24 | 120348 | 17395 | 29814711 |
Asthenia | 20.25 | 9.98 | 707 | 119665 | 220583 | 29611523 |
Apparent life threatening event | 20.23 | 9.98 | 12 | 120360 | 207 | 29831899 |
Drug interaction | 20.05 | 9.98 | 630 | 119742 | 198938 | 29633168 |
Hepatocellular carcinoma | 19.67 | 9.98 | 7 | 120365 | 9603 | 29822503 |
Progressive multifocal leukoencephalopathy | 19.44 | 9.98 | 6 | 120366 | 9007 | 29823099 |
Fluid retention | 19.33 | 9.98 | 45 | 120327 | 24953 | 29807153 |
Mental status changes | 19.31 | 9.98 | 231 | 120141 | 36848 | 29795258 |
Respiratory rate increased | 19.30 | 9.98 | 79 | 120293 | 8836 | 29823270 |
Anion gap abnormal | 19.21 | 9.98 | 10 | 120362 | 132 | 29831974 |
Apnoea | 19.10 | 9.98 | 62 | 120310 | 6196 | 29825910 |
Migraine | 18.98 | 9.98 | 102 | 120270 | 12772 | 29819334 |
Transaminases increased | 18.93 | 9.98 | 160 | 120212 | 23297 | 29808809 |
Injection site pain | 18.64 | 9.98 | 61 | 120311 | 30249 | 29801857 |
Renal papillary necrosis | 18.51 | 9.98 | 10 | 120362 | 143 | 29831963 |
Osteonecrosis of jaw | 18.34 | 9.98 | 29 | 120343 | 18589 | 29813517 |
Plasma cell myeloma | 18.09 | 9.98 | 133 | 120239 | 53329 | 29778777 |
Psoriatic arthropathy | 18.08 | 9.98 | 22 | 120350 | 15739 | 29816367 |
Dizziness | 17.76 | 9.98 | 623 | 119749 | 194286 | 29637820 |
Bone marrow failure | 17.59 | 9.98 | 61 | 120311 | 29724 | 29802382 |
Decreased appetite | 17.37 | 9.98 | 464 | 119908 | 149446 | 29682660 |
Body temperature increased | 17.19 | 9.98 | 110 | 120262 | 14670 | 29817436 |
Dyspnoea | 17.14 | 9.98 | 1132 | 119240 | 332163 | 29499943 |
Angina pectoris | 17.07 | 9.98 | 61 | 120311 | 29457 | 29802649 |
Asthma | 17.02 | 9.98 | 81 | 120291 | 36093 | 29796013 |
Off label use | 16.75 | 9.98 | 825 | 119547 | 248465 | 29583641 |
Blood triglycerides increased | 16.69 | 9.98 | 19 | 120353 | 13998 | 29818108 |
Maternal exposure before pregnancy | 16.61 | 9.98 | 13 | 120359 | 359 | 29831747 |
Administration site pain | 16.54 | 9.98 | 10 | 120362 | 179 | 29831927 |
Immune reconstitution inflammatory syndrome | 16.42 | 9.98 | 8 | 120364 | 9093 | 29823013 |
Therapeutic product effect incomplete | 16.37 | 9.98 | 75 | 120297 | 33759 | 29798347 |
Wrong technique in product usage process | 16.33 | 9.98 | 67 | 120305 | 31088 | 29801018 |
Diabetes mellitus | 16.24 | 9.98 | 100 | 120272 | 41765 | 29790341 |
Corneal abscess | 16.18 | 9.98 | 6 | 120366 | 32 | 29832074 |
Therapeutic response shortened | 16.18 | 9.98 | 41 | 120331 | 3559 | 29828547 |
Glycosylated haemoglobin increased | 16.15 | 9.98 | 9 | 120363 | 9482 | 29822624 |
Brain oedema | 16.14 | 9.98 | 95 | 120277 | 12303 | 29819803 |
Granulomatosis with polyangiitis | 16.12 | 9.98 | 19 | 120353 | 882 | 29831224 |
Chronic gastrointestinal bleeding | 15.98 | 9.98 | 11 | 120361 | 248 | 29831858 |
Hypertension neonatal | 15.86 | 9.98 | 4 | 120368 | 3 | 29832103 |
Vital functions abnormal | 15.82 | 9.98 | 8 | 120364 | 99 | 29832007 |
Anion gap increased | 15.80 | 9.98 | 26 | 120346 | 1655 | 29830451 |
Disease progression | 15.73 | 9.98 | 226 | 120146 | 79648 | 29752458 |
Feeling abnormal | 15.67 | 9.98 | 149 | 120223 | 56607 | 29775499 |
Hepatitis C | 15.61 | 9.98 | 18 | 120354 | 13187 | 29818919 |
Cytokine release syndrome | 15.54 | 9.98 | 80 | 120292 | 9853 | 29822253 |
Graft versus host disease | 15.38 | 9.98 | 11 | 120361 | 10139 | 29821967 |
Pemphigus | 15.37 | 9.98 | 22 | 120350 | 1239 | 29830867 |
Visual acuity reduced | 15.31 | 9.98 | 25 | 120347 | 15821 | 29816285 |
Poor venous access | 15.30 | 9.98 | 32 | 120340 | 2448 | 29829658 |
Malaise | 15.12 | 9.98 | 534 | 119838 | 166428 | 29665678 |
Mucosal inflammation | 15.11 | 9.98 | 67 | 120305 | 30427 | 29801679 |
Flushing | 15.03 | 9.98 | 183 | 120189 | 29309 | 29802797 |
Venoocclusive liver disease | 15.00 | 9.98 | 4 | 120368 | 6609 | 29825497 |
Renal impairment | 14.94 | 9.98 | 243 | 120129 | 83941 | 29748165 |
Anti-erythrocyte antibody positive | 14.94 | 9.98 | 6 | 120366 | 41 | 29832065 |
Ear infection | 14.92 | 9.98 | 64 | 120308 | 7310 | 29824796 |
Haemolysis | 14.81 | 9.98 | 63 | 120309 | 7168 | 29824938 |
Environmental exposure | 14.69 | 9.98 | 11 | 120361 | 284 | 29831822 |
Pulmonary oedema | 14.52 | 9.98 | 253 | 120119 | 43722 | 29788384 |
Administration site erythema | 14.18 | 9.98 | 7 | 120365 | 82 | 29832024 |
Cerebral haemorrhage | 14.13 | 9.98 | 76 | 120296 | 32811 | 29799295 |
Memory impairment | 13.80 | 9.98 | 90 | 120282 | 37084 | 29795022 |
Malignant neoplasm progression | 13.72 | 9.98 | 206 | 120166 | 72081 | 29760025 |
Blood count abnormal | 13.65 | 9.98 | 16 | 120356 | 11636 | 29820470 |
Cerebral infarction | 13.64 | 9.98 | 57 | 120315 | 26316 | 29805790 |
Electrocardiogram QRS complex prolonged | 13.62 | 9.98 | 43 | 120329 | 4234 | 29827872 |
Lung neoplasm malignant | 13.60 | 9.98 | 25 | 120347 | 15107 | 29816999 |
Haematotoxicity | 13.50 | 9.98 | 4 | 120368 | 6166 | 29825940 |
Oedema peripheral | 13.48 | 9.98 | 323 | 120049 | 105509 | 29726597 |
Throat tightness | 13.47 | 9.98 | 61 | 120311 | 7131 | 29824975 |
Bilirubin urine present | 13.08 | 9.98 | 7 | 120365 | 98 | 29832008 |
Endocardial fibrosis | 13.00 | 9.98 | 5 | 120367 | 30 | 29832076 |
Myopathy | 12.99 | 9.98 | 14 | 120358 | 10572 | 29821534 |
Sopor | 12.97 | 9.98 | 15 | 120357 | 10976 | 29821130 |
Peritonitis bacterial | 12.93 | 9.98 | 16 | 120356 | 11362 | 29820744 |
Ammonia increased | 12.93 | 9.98 | 42 | 120330 | 4199 | 29827907 |
Pulmonary congestion | 12.82 | 9.98 | 89 | 120283 | 12198 | 29819908 |
Crystal urine present | 12.81 | 9.98 | 10 | 120362 | 275 | 29831831 |
Balance disorder | 12.72 | 9.98 | 90 | 120282 | 36403 | 29795703 |
Febrile neutropenia | 12.68 | 9.98 | 537 | 119835 | 106156 | 29725950 |
Blood ethanol increased | 12.53 | 9.98 | 11 | 120361 | 358 | 29831748 |
Osteonecrosis | 12.51 | 9.98 | 29 | 120343 | 16106 | 29816000 |
Leukopenia | 12.47 | 9.98 | 155 | 120217 | 56004 | 29776102 |
Vitello-intestinal duct remnant | 12.43 | 9.98 | 7 | 120365 | 109 | 29831997 |
Cardiac disorder | 12.21 | 9.98 | 102 | 120270 | 39791 | 29792315 |
Acute myocardial infarction | 12.18 | 9.98 | 145 | 120227 | 52794 | 29779312 |
Infusion site bruising | 12.13 | 9.98 | 9 | 120363 | 229 | 29831877 |
Infusion site rash | 12.13 | 9.98 | 10 | 120362 | 298 | 29831808 |
Chronic obstructive pulmonary disease | 11.94 | 9.98 | 123 | 120249 | 46003 | 29786103 |
Analgesic drug level above therapeutic | 11.90 | 9.98 | 9 | 120363 | 236 | 29831870 |
Labelled drug-drug interaction medication error | 11.78 | 9.98 | 15 | 120357 | 10523 | 29821583 |
Hepatic haematoma | 11.70 | 9.98 | 12 | 120360 | 476 | 29831630 |
Infusion site nodule | 11.67 | 9.98 | 6 | 120366 | 77 | 29832029 |
Drug ineffective for unapproved indication | 11.64 | 9.98 | 16 | 120356 | 10864 | 29821242 |
Hyperlipidaemia | 11.61 | 9.98 | 24 | 120348 | 13883 | 29818223 |
Agitation | 11.60 | 9.98 | 292 | 120080 | 53781 | 29778325 |
Stomatitis | 11.55 | 9.98 | 95 | 120277 | 37184 | 29794922 |
Rheumatoid arthritis | 11.52 | 9.98 | 231 | 120141 | 40966 | 29791140 |
Monocyte percentage increased | 11.41 | 9.98 | 16 | 120356 | 884 | 29831222 |
Ultrasound liver abnormal | 11.40 | 9.98 | 7 | 120365 | 129 | 29831977 |
Adrenergic syndrome | 11.21 | 9.98 | 6 | 120366 | 84 | 29832022 |
Vessel puncture site bruise | 11.18 | 9.98 | 5 | 120367 | 46 | 29832060 |
Urticaria | 11.16 | 9.98 | 293 | 120079 | 54313 | 29777793 |
Drug screen positive | 11.13 | 9.98 | 41 | 120331 | 4366 | 29827740 |
Anti-thyroid antibody positive | 11.08 | 9.98 | 5 | 120367 | 47 | 29832059 |
Infusion site erythema | 11.05 | 9.98 | 22 | 120350 | 1624 | 29830482 |
Prescribed overdose | 10.86 | 9.98 | 11 | 120361 | 8550 | 29823556 |
Urobilinogen urine increased | 10.71 | 9.98 | 10 | 120362 | 353 | 29831753 |
Liver transplant | 10.66 | 9.98 | 30 | 120342 | 2772 | 29829334 |
Medication overuse headache | 10.65 | 9.98 | 5 | 120367 | 52 | 29832054 |
Post transplant lymphoproliferative disorder | 10.63 | 9.98 | 4 | 120368 | 5302 | 29826804 |
General physical health deterioration | 10.63 | 9.98 | 313 | 120059 | 99631 | 29732475 |
Pathogen resistance | 10.45 | 9.98 | 11 | 120361 | 8399 | 29823707 |
Antineutrophil cytoplasmic antibody positive | 10.29 | 9.98 | 11 | 120361 | 458 | 29831648 |
Necrotising enterocolitis neonatal | 10.14 | 9.98 | 6 | 120366 | 103 | 29832003 |
Bacterial test | 10.08 | 9.98 | 7 | 120365 | 160 | 29831946 |
Therapeutic response decreased | 10.06 | 9.98 | 57 | 120315 | 24292 | 29807814 |
Ureteric obstruction | 10.04 | 9.98 | 18 | 120354 | 1228 | 29830878 |
Cytomegalovirus infection | 10.01 | 9.98 | 55 | 120317 | 23619 | 29808487 |
Source | Code | Description |
---|---|---|
ATC | D11AX26 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
ATC | N06BC01 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Xanthine derivatives |
ATC | V04CG30 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for gastric secretion |
FDA CS | M0023046 | Xanthines |
FDA PE | N0000175729 | Central Nervous System Stimulation |
FDA EPC | N0000175739 | Central Nervous System Stimulant |
FDA EPC | N0000175790 | Methylxanthine |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D058914 | Purinergic Antagonists |
MeSH PA | D058915 | Purinergic P1 Receptor Antagonists |
CHEBI has role | CHEBI:25435 | mutagens |
CHEBI has role | CHEBI:35337 | analeptic drug |
CHEBI has role | CHEBI:35471 | psychopharmaceuticals |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:35703 | xenobiotic |
CHEBI has role | CHEBI:50218 | phosphodiesterase inhibitors |
CHEBI has role | CHEBI:50925 | serine/threonine protein kinase inhibitors |
CHEBI has role | CHEBI:53121 | adenosine a2a receptor antagonists |
CHEBI has role | CHEBI:60809 | adjuvants |
CHEBI has role | CHEBI:64047 | food additives |
CHEBI has role | CHEBI:67114 | ryrs activator |
CHEBI has role | CHEBI:71232 | adenosine receptor antagonists |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:76946 | fungal metabolites |
CHEBI has role | CHEBI:78298 | environmental contaminants |
CHEBI has role | CHEBI:85234 | human blood serum metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Sinus headache | indication | 4969004 | |
Apnea in the newborn | indication | 13094009 | |
Pain | indication | 22253000 | |
Migraine | indication | 37796009 | DOID:6364 |
Joint pain | indication | 57676002 | |
Allergic rhinitis | indication | 61582004 | |
Nasal discharge | indication | 64531003 | |
Nasal congestion | indication | 68235000 | |
Common cold | indication | 82272006 | DOID:10459 |
Vascular headache | indication | 128187005 | |
Backache | indication | 161891005 | |
Cluster headache syndrome | indication | 193031009 | |
Spasticity | indication | 221360009 | |
Headache disorder | indication | 230461009 | |
Dysmenorrhea | indication | 266599000 | |
Influenza-like symptoms | indication | 315642008 | |
Tension-type headache | indication | 398057008 | |
Cluster Headache Prevention | indication | ||
Fatigue | off-label use | 84229001 | |
Urinary incontinence | off-label use | 165232002 | |
Obesity | off-label use | 414916001 | DOID:9970 |
Brain damage | contraindication | 2470005 | |
Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Gastritis | contraindication | 4556007 | DOID:4029 |
Hypophosphatemia | contraindication | 4996001 | |
Tachyarrhythmia | contraindication | 6285003 | |
Suicidal thoughts | contraindication | 6471006 | |
Dependent drug abuse | contraindication | 6525002 | |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Alcoholism | contraindication | 7200002 | |
Alcohol withdrawal delirium | contraindication | 8635005 | |
Hyperammonemia | contraindication | 9360008 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Asthenia | contraindication | 13791008 | |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Hyperkalemia | contraindication | 14140009 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Constipation | contraindication | 14760008 | DOID:2089 |
Chronic disease of respiratory system | contraindication | 17097001 | |
Mood swings | contraindication | 18963009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
Ventricular tachycardia | contraindication | 25569003 | |
Alcohol intoxication | contraindication | 25702006 | |
Complete atrioventricular block | contraindication | 27885002 | |
Shock | contraindication | 27942005 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Hypovolemia | contraindication | 28560003 | |
Orthostatic hypotension | contraindication | 28651003 | |
Acute cerebrovascular insufficiency | contraindication | 29322000 | |
Atony of colon | contraindication | 29479008 | |
Hypercapnia | contraindication | 29596007 | |
Dehydration | contraindication | 34095006 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Depressive disorder | contraindication | 35489007 | |
Acute hepatitis | contraindication | 37871000 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
Hypokalemia | contraindication | 43339004 | |
Body fluid retention | contraindication | 43498006 | |
Hyperactive behavior | contraindication | 44548000 | |
Fecal impaction | contraindication | 44635007 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
Chronic heart failure | contraindication | 48447003 | |
Bradycardia | contraindication | 48867003 | |
Retroperitoneal fibrosis | contraindication | 49120005 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Acidosis | contraindication | 51387008 | |
Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
Gastrointestinal perforation | contraindication | 51875005 | |
Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
Nasal polyp | contraindication | 52756005 | |
Gastrectomy | contraindication | 53442002 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Peptic reflux disease | contraindication | 57643001 | |
Congenital myotonia, autosomal dominant form | contraindication | 57938005 | |
Acute nephropathy | contraindication | 58574008 | |
Leber's optic atrophy | contraindication | 58610003 | DOID:705 |
Hepatic failure | contraindication | 59927004 | |
Diarrhea | contraindication | 62315008 | |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Arterial thrombosis | contraindication | 65198009 | |
Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
Substance abuse | contraindication | 66214007 | |
Hypermagnesemia | contraindication | 66978005 | |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Hemorrhoids | contraindication | 70153002 | DOID:9746 |
Poisoning by acetaminophen | contraindication | 70273001 | |
Agoraphobia | contraindication | 70691001 | DOID:593 |
Arteriosclerotic vascular disease | contraindication | 72092001 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Factor II deficiency | contraindication | 73975000 | |
Reye's syndrome | contraindication | 74351001 | DOID:14525 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Urethral stricture | contraindication | 76618002 | |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Spastic paralysis | contraindication | 78403003 | |
Disturbance of salivary secretion | contraindication | 78948009 | |
Decreased respiratory function | contraindication | 80954004 | |
Injury of head | contraindication | 82271004 | |
Chronic idiopathic constipation | contraindication | 82934008 | |
Cor pulmonale | contraindication | 83291003 | DOID:8515 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Atrophic gastritis | contraindication | 84568007 | DOID:8929 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Pulmonary emphysema | contraindication | 87433001 | |
Gout | contraindication | 90560007 | DOID:13189 |
Chronic renal failure syndrome | contraindication | 90688005 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
Hemophilia | contraindication | 90935002 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Obstruction of duodenum | contraindication | 95532008 | DOID:3558 |
Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Prolonged QT interval | contraindication | 111975006 | |
Acute abdominal pain | contraindication | 116290004 | |
Procedure on urinary system | contraindication | 118677009 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Neoplasm of brain | contraindication | 126952004 | DOID:1319 |
von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
Seizure disorder | contraindication | 128613002 | |
Autonomic dysreflexia | contraindication | 129618003 | |
Bleeding | contraindication | 131148009 | |
Prolonged PR interval | contraindication | 164947007 | |
Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
Obsessive-compulsive disorder | contraindication | 191736004 | DOID:10933 |
Insomnia | contraindication | 193462001 | |
Partial atrioventricular block | contraindication | 195039008 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Impaired renal function disorder | contraindication | 197663003 | |
Coronary artery bypass graft | contraindication | 232717009 | |
Myocardial dysfunction | contraindication | 233928007 | |
Peripheral ischemia | contraindication | 233958001 | |
Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
Gastroparesis | contraindication | 235675006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Chronic diarrhea | contraindication | 236071009 | |
Hyporeninemic hypoaldosteronism | contraindication | 236464008 | |
Aluminum intoxication | contraindication | 236546003 | |
Bladder outflow obstruction | contraindication | 236645006 | |
Morbid obesity | contraindication | 238136002 | DOID:11981 |
Sepsis syndrome | contraindication | 238150007 | |
Pyloric obstruction | contraindication | 244815007 | |
Sleep automatism | contraindication | 247962006 | |
Raynaud's phenomenon | contraindication | 266261006 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Drowsy | contraindication | 271782001 | |
Exacerbation of asthma | contraindication | 281239006 | |
Cerebral ischemia | contraindication | 287731003 | |
Pregnancy, function | contraindication | 289908002 | |
Lesion of brain | contraindication | 301766008 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Familial hyperkalemic periodic paralysis | contraindication | 304737009 | DOID:14451 |
Panic disorder | contraindication | 371631005 | DOID:594 |
Coma | contraindication | 371632003 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Operation on gastrointestinal tract | contraindication | 386621005 | |
Hypoxia | contraindication | 389086002 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Cardiovascular event risk | contraindication | 395112001 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Peripheral vascular disease | contraindication | 400047006 | |
Respiratory insufficiency | contraindication | 409623005 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Central nervous system depression | contraindication | 418072004 | |
Porphyria | contraindication | 418470004 | |
Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant | contraindication | 422681000 | |
Dysfunction of sphincter of Oddi | contraindication | 430887001 | |
Fibrosis of pleura | contraindication | 442110002 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Hypertensive urgency | contraindication | 443482000 | |
Acute erosive gastritis | contraindication | 444926003 | |
Smokes tobacco daily | contraindication | 449868002 | |
Severe dehydration | contraindication | 450316000 | |
Acute exacerbation of asthma | contraindication | 708038006 | |
Ergot Alkaloid Toxicity | contraindication | ||
Acute Thromboembolic Stroke | contraindication | ||
Organic Cardiac Disease | contraindication | ||
Severe Pruritus | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.86 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Adenosine receptor A2b | GPCR | ANTAGONIST | Ki | 4.77 | WOMBAT-PK | CHEMBL | |||
Adenosine receptor A1 | GPCR | ANTAGONIST | Ki | 4.97 | IUPHAR | CHEMBL | |||
Adenosine receptor A2a | GPCR | ANTAGONIST | Ki | 5.61 | CHEMBL | CHEMBL | |||
Acetylcholinesterase | Enzyme | IC50 | 5.14 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.31 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | ANTAGONIST | Ki | 4.33 | WOMBAT-PK | ||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | IC50 | 4.12 | CHEMBL | |||||
Guanine deaminase | Enzyme | Ki | 4.99 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 4.54 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 4.77 | CHEMBL | |||||
Adenosine A2a receptor | Unclassified | Ki | 4.10 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 5.03 | CHEMBL | |||||
Adenosine A2 receptor | GPCR | Ki | 4.57 | CHEMBL | |||||
Glycogen phosphorylase, muscle form | Enzyme | IC50 | 4.13 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 4 | CHEMBL | |||||
Adenosine receptor | GPCR | Ki | 4.22 | CHEMBL | |||||
Adenosine receptor A2b | Unclassified | ANTAGONIST | Ki | 4.89 | IUPHAR |
ID | Source |
---|---|
4017537 | VUID |
N0000145919 | NUI |
D00528 | KEGG_DRUG |
69-22-7 | SECONDARY_CAS_RN |
4017537 | VANDF |
4018995 | VANDF |
C0006644 | UMLSCUI |
CHEBI:27732 | CHEBI |
CFF | PDB_CHEM_ID |
CHEMBL113 | ChEMBL_ID |
2519 | PUBCHEM_CID |
CHEMBL1200569 | ChEMBL_ID |
DB00201 | DRUGBANK_ID |
D002110 | MESH_DESCRIPTOR_UI |
C026189 | MESH_SUPPLEMENTAL_RECORD_UI |
407 | IUPHAR_LIGAND_ID |
3G6A5W338E | UNII |
1886 | RXNORM |
11623 | MMSL |
17093 | MMSL |
4318 | MMSL |
4319 | MMSL |
46084 | MMSL |
4939 | MMSL |
d00801 | MMSL |
000600 | NDDF |
000601 | NDDF |
23068001 | SNOMEDCT_US |
255641001 | SNOMEDCT_US |
91107009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Fiorinal with Codeine | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0023-6010 | CAPSULE | 40 mg | ORAL | NDA | 36 sections |
Fiorinal | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0023-6146 | CAPSULE | 40 mg | ORAL | NDA | 23 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-2000 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 13 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-2001 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 15 sections |
ExcedrinExtra Strength Geltabs | HUMAN OTC DRUG LABEL | 3 | 0067-2021 | TABLET, COATED | 65 mg | ORAL | OTC monograph not final | 14 sections |
ExcedrinMigraine Geltabs | HUMAN OTC DRUG LABEL | 3 | 0067-2035 | TABLET, COATED | 65 mg | ORAL | NDA | 14 sections |
EXCEDRINMIGRAINE | HUMAN OTC DRUG LABEL | 3 | 0067-2039 | TABLET, FILM COATED | 65 mg | ORAL | NDA | 15 sections |
ExcedrinMigraine | HUMAN OTC DRUG LABEL | 3 | 0067-2040 | TABLET, FILM COATED | 65 mg | ORAL | NDA | 16 sections |
ExcedrinTension Headache | HUMAN OTC DRUG LABEL | 2 | 0067-8139 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 15 sections |
EXCEDRINMIGRAINE | HUMAN OTC DRUG LABEL | 3 | 0067-8201 | TABLET, FILM COATED | 65 mg | ORAL | NDA | 15 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-8202 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 15 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-8203 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 15 sections |
good sense migraine formula | HUMAN OTC DRUG LABEL | 3 | 0113-0374 | TABLET, FILM COATED | 65 mg | ORAL | ANDA | 15 sections |
good sense stay awake | HUMAN OTC DRUG LABEL | 1 | 0113-0409 | TABLET | 200 mg | ORAL | OTC monograph final | 14 sections |
basic care migraine relief | HUMAN OTC DRUG LABEL | 3 | 0113-7374 | TABLET, FILM COATED | 65 mg | ORAL | ANDA | 15 sections |
PANULLDOLExtra | HUMAN OTC DRUG LABEL | 2 | 0135-0620 | TABLET, FILM COATED | 65 mg | ORAL | OTC monograph not final | 16 sections |
Butalbital, Acetaminophen, and Caffeine | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0143-0170 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
ERGOTAMINE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-2120 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Bayer Headache | HUMAN OTC DRUG LABEL | 2 | 0280-0064 | TABLET | 32.50 mg | ORAL | OTC monograph not final | 14 sections |
Bayer Back and BodyExtra Strength | HUMAN OTC DRUG LABEL | 2 | 0280-2150 | TABLET | 35.50 mg | ORAL | OTC monograph not final | 15 sections |
Midol Complete | HUMAN OTC DRUG LABEL | 3 | 0280-8005 | TABLET | 60 mg | ORAL | OTC monograph not final | 17 sections |
Midol CompleteGelcaps | HUMAN OTC DRUG LABEL | 3 | 0280-8015 | TABLET, COATED | 60 mg | ORAL | OTC monograph not final | 16 sections |
Extra Strength Headache Relief | HUMAN OTC DRUG LABEL | 3 | 0363-0021 | CAPSULE | 65 mg | ORAL | OTC monograph not final | 16 sections |
Headache ReliefExtra Strength | HUMAN OTC DRUG LABEL | 3 | 0363-0159 | TABLET, FILM COATED | 65 mg | ORAL | OTC MONOGRAPH NOT FINULLL | 15 sections |
Stay AwakeMaximum Strength | HUMAN OTC DRUG LABEL | 1 | 0363-0226 | TABLET | 200 mg | ORAL | OTC MONOGRAPH FINULLL | 13 sections |
Menstrual ReliefMaximum Strength | HUMAN OTC DRUG LABEL | 3 | 0363-0252 | TABLET | 60 mg | ORAL | OTC MONOGRAPH NOT FINULLL | 16 sections |
migraine relief | HUMAN OTC DRUG LABEL | 3 | 0363-0374 | TABLET, FILM COATED | 65 mg | ORAL | ANDA | 15 sections |
Tension Headache Relief | HUMAN OTC DRUG LABEL | 2 | 0363-0428 | TABLET, FILM COATED | 65 mg | ORAL | OTC MONOGRAPH NOT FINULLL | 15 sections |
Extra Strength Back and Body | HUMAN OTC DRUG LABEL | 2 | 0363-0431 | TABLET, FILM COATED | 32.50 mg | ORAL | OTC monograph not final | 15 sections |
Headache ReliefExtra Strength | HUMAN OTC DRUG LABEL | 3 | 0363-0443 | TABLET, FILM COATED | 65 mg | ORAL | OTC MONOGRAPH NOT FINULLL | 15 sections |